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Abstract
This study examined associations of sleep and minutes spent in moderate-vigorous physical 
activity (MVPA) with C-reactive protein (CRP) and interleukin (IL)-6 among persons living with 
HIV (PLWH). Cross-sectional analyses (n=45) focused on associations of inflammatory outcomes 
(i.e., CRP and IL-6) with actigraph-derived sleep duration, latency, and efficiency; bedtime; wake 
time; and wake-after-sleep-onset; as well as MVPA. Least square means for CRP and IL-6 by 
levels of sleep and MVPA were computed from general linear models. Individuals below the 
median of sleep duration, above the median for bedtime, and below the median of MVPA minutes 
had higher CRP or IL-6 levels. Generally, individuals with both low MVPA and poor sleep 
characteristics had higher inflammation levels than those with more MVPA and better sleep. 
Understanding the combined impact of multiple lifestyle/behavioral factors on inflammation could 
inform intervention strategies to reduce inflammation and therefore, chronic disease risk.
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Sleep is a physiological necessity. Disrupted sleep has been associated with a host of chronic 
physical and mental disorders, abnormal hormone and immune functioning, and mortality 
[1-4]. It is possible that mechanisms involving inflammatory pathways may partially explain 
the associations between sleep disruption and chronic disease. Chronic inflammation due to 
repeated insults or ‘injuries’ (e.g., tobacco use, chronic infection, chronic pain, repeated 
sleep disruption) is an underlying pathophysiological process that has been associated with 
numerous chronic conditions including cancer, diabetes, cardiovascular disease (CVD), 
obesity, metabolic syndrome, and mortality [5-7]. Systemic inflammation most likely 
involves a complex causal web involving many factors, including bio-behavioral influences 
[3].
The literature describing relationships between obstructive sleep apnea (OSA) and 
inflammation is extensive [8]. A recent meta-analysis including 51 studies found that, 
compared to controls, individuals with OSA had statistically greater C-reactive protein 
(CRP), tumor necrosis factor-α (TNF-α), and interleukin (IL)-6 [9]. Additionally, numerous 
experimental studies have indicated increased levels of white blood cells, TNF-α, IL-6 or 
CRP following sleep deprivation compared to normal sleeping conditions [10-12]. Most of 
the existing literature based on observational studies focusing on sleep and inflammation has 
been centered on sleep duration. Generally, short sleep or reduced sleep duration over time 
have been associated with increased inflammation [13-16]. For example, A study by Ferrie 
et al., using the Whitehall II study participants, found that reduction in sleep duration of one 
hour from the 1991/1994 to the 1997/1999 cycles was associated with an 8.1% increase and 
4.5% increase in CRP and IL-6 (both p<0.01), respectively [13]. Long sleep duration also 
has been associated with inflammation [14,15,17,18]. However, there is some inconsistency 
in definitions of short and long sleep duration, as well as statistical significance of findings 
between studies. Poor subjective sleep quality (as assessed by the Pittsburgh Sleep Quality 
Index), symptoms associated with worse sleep quality, and self-reported sleep debt also have 
been associated with elevated inflammation [19-24]. However, several studies have found 
no association between certain disrupted or inadequate sleep measures and inflammation 
[25-28]. Additionally, many of these previous studies have been limited to subjective 
measures of sleep [13-17,19,20,22,23,27,28].
Physical activity is one lifestyle factor that has been associated with both better sleep and 
reduced inflammation. Although intense bouts of physical activity have been shown to 
increase inflammation, long-term physical activity and greater cardiorespiratory fitness have 
been shown to lower levels of inflammation biomarkers [3,29]. The effects of physical 
activity on sleep might be moderated by the duration, intensity, and timing of physical 
activity. However, in general, increased sleep and higher sleep quality have been associated 
with regular physical activity [30-32]. Of particular interest is the combined effect of sleep 
and physical activity on inflammation, which has yet to be fully elucidated among human 
populations. Using animal models, Zielinski et al., found reductions in IL-6 and TNF levels 
following 11 weeks of exercise training in wild-type mice under normal sleep conditions. 
However, exercise had no effect on IL-6 or TNF levels among sleep-restricted mice [33].
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Persons living with HIV (PLWH) have often reported poor sleep quality and disruptions in 
routine sleeping habits that are believed to be caused by factors such as psychological 
distress, low socio-economic status, and viral and pharmacological side-effects (e.g. 
peripheral neuropathy resulting in chronic pain, migraines, nausea, insomnia) [34-36]. These 
sleep disruptions, in turn, have the potential to contribute to increased levels of fatigue and 
sedentary behavior. As least partly due to low levels of daily physical activity, drastic 
reductions in cardiorespiratory fitness (i.e. VO2max) have been found among HIV/AIDS 
patients [37-39], which have been consistently reported since the discovery of HIV both 
before and after the initiation of anti-retroviral therapy (ART) [40]. Thus, it seems that these 
reductions in fitness are a result of more than just HIV-related treatments.
In addition to disturbances in sleep quality, PLWH also exhibit a state of chronic 
inflammation. The extent to which this is a result of HIV infection, ART toxicities, or daily 
lifestyle habits is not well understood; it is likely that a combination of factors is responsible 
[41]. Although ART has successfully halted viral replication and therefore viral load, PLWH 
receiving ART still exhibit increased levels of inflammation [41]. For example, a recent 
study by Brigham and colleagues compared a sample of men who were HIV-negative with 
two groups of HIV-positive men (those receiving ART and those who were not). They found 
that plasma levels of TNF-alpha and IL-6 were higher only in those who were HIV+ with 
moderate to severe OSA compared to those with no OSA or mild levels of OSA independent 
of HIV-related covariates or treatment [42]. Other studies have shown increased plasma 
levels of various cytokines and markers of inflammation among PLWH regardless of ART 
treatment [43,44]. However, many of these studies did not incorporate sleep-related metrics 
that have been associated with inflammation in numerous non-HIV populations. Chronic 
conditions associated with inflammation such as CVD, type II diabetes, cancer, 
neurocognitive dysfunction, frailty, and many others, are often seen at higher-than-expected 
rates in elderly populations with HIV or AIDS [45]. Recently, it has become a top priority 
among healthcare professionals to discover new ways that may suppress immune system 
activation.
This current study was designed to examine the combined association of objectively 
measured physical activity and sleep with inflammatory levels among PLWH who had been 
recruited for a randomized controlled trial of exercise training [46]. We hypothesized that 
levels of CRP and IL-6 would be greater among individuals with ‘unhealthy’ sleep 
characteristics (e.g., later bed or wake times, short sleep duration, long sleep latency, low 
sleep efficiency, high wake-after-sleep-onset [WASO] minutes), which were objectively 
measured using BodyMedia’s SenseWear® physical activity armband. Additionally, we 
hypothesized that the combined effect of sleep and physical activity levels on inflammation 
would be greater than the effect of either exposure individually.
Methods
This cross-sectional study included baseline data from the larger home-based randomized 
control trial among PLWH. A complete description of the methodology, recruiting, and 
participant screening protocols for this home-based trial can be found elsewhere [46]. The 
research protocol was approved by the University of South Carolina Institutional Review 
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Board. Written informed consent was obtained from all participants prior to any data 
collection.
Participants
Study participants were from a local sample of PLWH in the greater Columbia and 
Charleston, South Carolina areas. Participants were recruited from local healthcare 
providers, flyers posted at HIV support group centers, and word of mouth. Data were 
obtained from a total of 45 PLWH (26 males and 19 females) currently taking ART who had 
valid SenseWear® armband data.
Independent Variables: Sleep and Physical Activity Assessment
Sleep and physical activity patterns were assessed for 7-10 days with the SenseWear® 
armband, a commercially available lightweight physical activity monitor that is worn on the 
upper left arm halfway between the acromion and olecranon processes. The SenseWear® 
armband uses tri-axial accelerometry technology augmented by 2 heat sensors (a thermistor-
based skin surface sensor and a heat flux sensor), and a galvanic skin response sensor. These 
four internal sensors turn on the monitor when detecting skin contact and measures total 
time the armband was worn, daily energy expenditure, step count, sleep, and the intensity, 
duration, and frequency of physical activity bouts [47,48]. All armband data were analyzed 
by computer-based software using demographic information (sex and age), height and 
weight applied to proprietary algorithms. Moderate-vigorous physical activity (MVPA) 
minutes, measured by the SenseWear® armband, were defined as any activity ≥3 metabolic 
equivalent. Levels of MVPA were divided into 2 groups based on a median split (<70 vs. 
≥70 mins/day of MVPA).
Using the latest proprietary algorithms from the SenseWear® software (SenseWear 
Professional software version 7.0; BodyMedia Inc.) each recorded minute-epoch has a sleep/
wake designation. A few studies have indicated high correlation, percent agreement, or 
intraclass correlation between wrist actigraphy or polysomnography (PSG) and the 
SenseWear® armband for total sleep time, WASO, and sleep efficiency [49-52]. Only 
nighttime sleep was characterized. Participants did not record daytime activities during non-
wear periods; therefore, making it difficult to reliably and fully discern daytime napping. 
Sleep onset was defined as the first of three consecutive minutes when the subject was 
asleep, in conjunction with at least ten minutes lying down. Wake time was defined as the 
first of 90 consecutive minutes of wakefulness. After removing possible ‘daytime’ naps (i.e., 
sleep bouts <4 hours ending between noon and 10PM), it was still possible that individuals 
had multiple sleep bouts for a single day. Multiple bouts per day were further reviewed and 
either combined to create one nighttime bout or considered naps that did not meet the 
standard definition of naps above. Total sleep time was the sum of all sleep minutes during 
the nighttime sleep bout. Sleep latency was the sum of minutes between lying down and 
falling asleep. WASO required subjects to be scored awake for two consecutive minutes 
after the onset of sleep and summed until the final wake time. Lastly, sleep efficiency was 
defined as total sleep time divided by the length of the nighttime sleep bout. Subjects had to 
have a least three nights of evaluable data to be included in the analyses. Due to the limited 
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sample size (n=45), a median split for each sleep metric was created instead of more 
standard cut-points (see Table 3 for cut-points).
Sleep metric categories were then combined with MVPA categories. For example, sleep 
efficiency and MVPA minutes were combined into the following categories: low sleep 
efficiency and low MVPA minutes (‘most unhealthy’ category), low sleep efficiency and 
high MVPA minutes, high sleep efficiency and low MVPA minutes, and high sleep 
efficiency and high MVPA minutes (‘healthiest’ category) with the comparison of interest 
being between the ‘healthiest’ and ‘most unhealthy’ categories (see Table 3, supplemental 
Table A displays the full results and p-values for each category compared to the ‘healthiest’ 
category).
Outcomes: CRP and IL-6
Blood draws occurred in the early morning following a 12-hour fast. Blood serum was 
separated via centrifuge and stored in a -80oC freezer until analysis. CRP and IL-6 (higher 
values indicating greater systemic inflammation) were measured in duplicate by the 
LabCorp Clinical Trials Division using a standard protocol for immunochemiluminometric 
assays at a central location that undergoes rigorous quality assurance testing to deliver high 
accuracy and reliability.
Clinical assessment and Self-Reported Measures
Clinical assessments included measures of resting blood pressure, waist and hip 
circumference, height, and weight. Waist-to-hip ratio and body mass index (BMI, kg/m2) 
were calculated. Basic demographic (e.g., race, gender, income, education) information was 
obtained, as well as sexual orientation, putative route of HIV infection, smoking status, and 
comorbidities. Numerous psychosocial and behavior questionnaires (e.g., social support for 
physical activity [53], decisional balance [54], perceived stress scale [55], Michigan alcohol 
screening test [56], process of change [57], and SF-36 [58]) also were examined as potential 
confounders.
Statistical Analyses
All analyses were performed using SAS® version 9.3 (Cary, NC). Descriptive statistics for 
selected covariates and the sleep metrics were computed using frequencies or means for 
categorical and continuous variables, respectively. Variable selection began as a series of 
bivariate analyses (sleep metric + covariate). Covariates with a p-value of ≤0.20 were added 
to a ‘full’ model. A backward elimination procedure was then used to develop ‘final’ models 
that included all variables that, when removed from the model, changed the beta coefficient 
of the sleep metric by at least 10%. All statistically significant (p<0.05) covariates also were 
kept in the model.
General linear models were used to compute least square means along with 95% confidence 
intervals (95%CI) for CRP and IL-6 among median splits of each sleep metric and MVPA 
minutes, and among the categories of the combined sleep and MVPA measures.
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Most participants (58% male) had at least some college education (66%), and were 
predominately single (78%), black (82%), current or former smokers (63%), and overweight 
(mean BMI 29.9±6.7 kg/m2). Additionally, a majority of the participants had an annual 
household income <$30,000 (67%), 88% had HIV (of which half were symptomatic), as 
opposed to having AIDS (which was based on self-report), and had relatively high crude 
baseline levels of CRP (5.5±6.1 mg/L) and IL-6 (3.6±1.8 pg/mL) (Table 1). The average age 
was 47.1±9.4 years. The mean sleep onset and wake time were 12:00AM and 7:32AM, 
respectively. Participants spent, on average, ≈7.5 hours in bed, but had an average sleep 
duration of only 5.5 hours. This was reflected by a high mean WASO of 85 minutes. Mean 
sleep efficiency was only 74% (data not tabulated).
Results of analyses examining the relationship between each sleep metric or MVPA minutes 
and inflammation are shown in Table 2. Participants below the median of total sleep time 
(i.e., <339 minutes) had higher CRP values (6.9 vs. 2.0 mg/L, p=0.05) compared to those 
above the median. For IL-6, those above the median of sleep onset (i.e., >11:46PM; 4.8 vs. 
3.7 pg/mL, p=0.01) and those below the median of total sleep time (4.9 vs. 3.6 pg/mL, 
p=<0.01) had elevated values compared to those below the median of sleep onset and above 
the median of total sleep time, respectively. Participants performing at least 70 minutes of 
MVPA per day had lower CRP values compared to participants with <70 minutes of MVPA 
(1.6 vs. 4.6 mg/L, p=0.04). However, no statistically significant association was observed 
between daily average MVPA minutes and IL-6 (Table 2).
Table 3 displays the results for combined sleep and MVPA. For CRP, participants with a 
later sleep onset and lower MVPA minutes compared to participants with earlier sleep 
onsets and higher MVPA minutes (CRP=6.5 vs. 1.1 mg/L, p=0.03) showed statistically 
significantly greater values. Similarly, those with lower total sleep time and lower MVPA 
minutes compared to higher total sleep and higher MVPA minutes (CRP=6.7 vs. 1.0 mg/L, 
p=0.01) had higher CRP values. The same was true for those with lower sleep efficiency 
(i.e., <73%) and lower MVPA minutes compared to those with higher sleep efficiency and 
higher MVPA minutes (CRP=7.8 vs. 1.3 mg/L, p=0.02); and higher WASO (i.e., >85 
minutes) and lower MVPA minutes compared to lower WASO and higher MVPA minutes 
(CRP=3.9 vs. 1.0 mg/L, p=0.04). For IL-6, participants with later bedtimes and lower 
MVPA minutes compared to earlier bedtimes and higher MVPA minutes (IL-6=5.0 vs. 3.4 
pg/mL, p=0.02); and participants with lower total sleep time and lower MVPA minutes 
compared to higher total sleep and higher MVPA minutes (IL-6=5.3 vs. 4.0, p=0.02) had 
greater values.
Discussion
This study found that inflammation in PLWH was associated with various sleep metrics, 
especially later sleep onset and less total sleep time. Additionally, participants in the 
categories representing less MVPA and ‘less healthy’ sleep (i.e., later sleep onset, less total 
sleep time, lower sleep efficiency, and more WASO) had higher levels of CRP or IL-6. 
Generally, our findings of the associations of poor sleep with inflammation are consistent 
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with previous literature, which indicates that disturbed or inadequate sleep is associated with 
inflammation [9-24,59,60]. However, this is one of the first studies to perform such an 
analysis among PLWH.
The present study expands on these previous findings by showing associations between 
inflammation markers and objectively measured sleep duration, as well as other measures 
including sleep onset and wake times, sleep efficiency and latency, and WASO. However, 
comparisons to previous studies, although possible, can be difficult due to differing 
definitions of sleep measures. This is especially true for sleep duration. The current study 
utilized median splits due to the limited sample size. Therefore, shorter and longer sleep 
duration was below and above 5.75 hours, respectively, which is typically a lower cut-point 
for sleep duration than other studies. It should be noted, however, that objectively measured 
sleep duration is often about one hour less than subjective sleep duration [61].
The literature indicates that the relationship between inflammation and sleep is most likely 
described by a complex model involving numerous demographic and behavioral factors with 
several different pathways [62-65]. Physical activity is associated with both sleep and 
inflammation [3,30-32] and the combined impact of disturbed sleep and low levels of 
physical activity on inflammation may be stronger than either factor independently. In 
further support of combining the effect of sleep and physical activity, the current study 
observed that those in sleep metric categories indicative of ‘healthier’ sleep characteristics 
had between 16 and 55% greater average daily MVPA minutes compared to those in ‘less 
healthy’ sleep categories (data not shown). We hypothesized that the combined influence of 
both sleep and physical activity would tend to modify the effect on inflammation. This was 
supported by our results and by similar previous findings using mouse models [33]. This 
model is an oversimplification of the true causal pathway describing the relationship 
between sleep, lifestyle factors, and inflammation. This is especially true among populations 
living with a chronic condition such as HIV or AIDS.
For example, it is possible that the relationships observed in this study were, in-part, 
mediated by unmeasured factors associated with chronic pain (including lower back), 
arthritis, and other bone/joint problems (known to be associated with inflammation), poor 
sleep quality, and sedentary behavior, which sometimes are observed among PLWH. 
Although sleep and physical activity may influence inflammation among PLWH, their effect 
on disease progression (e.g., viral load) and how that further influences inflammation is not 
well understood. However, disturbed sleep clearly has a negative effect on immunity. 
Reports have shown decreases in T-cells (e.g. CD4+, CD3+, etc) in patients with poor sleep 
quality, as well as those with OSA [66-68]. However, these decrements in immunity due to 
sleep have not been shown to impact disease progression as indicated by HIV viral load. To 
our knowledge, the same is true for physical activity. The combined effect of reduced 
physical activity and disrupted sleep on inflammation, in conjunction with changes in 
disease progression among humans should be further explored, especially among those 
living with a chronic condition such as HIV or AIDS.
This study had several noteworthy strengths. Sleep and physical activity were both 
objectively measured using the SenseWear® armband. Several studies have used the 
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summary sleep measures provided by the proprietary algorithms from the SenseWear® 
armband [52,69,70]. However, few have taken advantage of the capacity to calculate sleep-
related parameters from the minute-by-minute sleep/wake designations, which are typically 
well correlated with other objective measures of sleep (e.g., PSG, wrist actigraphy) [49-51]. 
In addition to providing more evidence for an association between disturbed sleep and 
inflammation, this was one of the first studies to examine the combined effect of sleep and 
physical activity on inflammation using a population with a chronic condition (i.e., HIV or 
AIDS). Also, this study was able to examine numerous potential confounders, especially 
those related to psychosocial constructs.
In addition to the strengths, several limitations were present. As with other actigraphs, 
several reports indicate that the ability of the SenseWear® armband to differentiate between 
wakefulness and sleep becomes attenuated as sleep efficiency decreases [51,52]. This is of 
particular concern considering that PLWH have been shown to report high levels of chronic 
fatigue and sleep disturbances [34]. Additionally, common side effects often reported among 
certain ART medications include sleep disturbances, such as insomnia and poor sleep 
efficiency [35]. Considering the entire study sample was comprised of PLWH currently on a 
stable ART regimen, we were not only able to adjust for any potential ART-related 
differences, but it is suspected that any error would be non-differential in nature, therefore, 
biasing results towards the null. Although, this study had examined numerous confounders, 
potential residual confounding or lack of adjustment for unmeasured covariates cannot be 
completely ruled out. One of those covariates could potentially be chronic pain experienced 
by HIV-related peripheral neuropathy, a common comorbidity among PLWH [71,72]. We 
cannot overlook this as a potential cause of the increased markers of inflammation as well as 
the sleep disturbances within our study sample.
Other limitations include the limited sample size (n=45 for CRP; n=42 for IL-6) which may 
partially explain the lack of statistical significance for some results. The small sample size 
precluded comparisons by other factors, such as sex. Previous studies have found that the 
relationship between sleep and inflammation differs by sex, although there is some 
inconsistency [14,15,17,19,23,24,28]. For example, one study found the odds of a CRP 
value above 3.0 mg/L was greater among long sleepers (odds ratio (OR)=1.50, 95% 
confidence interval (95%CI)=1.05-2.14) or those with greater sleep disturbance (OR=1.29, 
95%CI=1.05-1.59), but only among men [17]. However, Suarez et al. found that, among 
women, sleep problems (i.e., overall poor sleep quality and increased sleep latency) were 
associated with elevated CRP [23]. It would have been optimal to provide more categories 
of the sleep parameters or to perform a sensitivity analysis to examine cut-point bias; the 
limited sample size made this difficult. However, this study still demonstrated numerous 
statistically significant relationships between sleep and inflammation. Also, we observed 
lower levels of adjusted CRP among those in the upper median of MVPA minutes compared 
to the lower median, providing further support for use of a median split for MVPA minutes. 
Lastly, causation is difficult to establish due to the cross-sectional nature of this study. It is 
possible that adverse effects of ART treatments or other factors associated with HIV could 
have influenced inflammation, which in turn affected sleep quality or ability to participate in 
physical activity [30].
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Reducing inflammation is an important step in diminishing the risk and burden of chronic 
disease, as well as moderating the risk of comorbidities among those currently living with a 
chronic disease. Proper sleep maintenance and participation in regular physical activity may 
help to reduce the risk of inflammation, thereby, reducing the risk of several chronic 
diseases [3,10,29]. Future studies with larger populations are necessary to further elucidate 
the combined effects of sleep and physical activity on inflammation, as well as to 
incorporate other lifestyle factors, such as diet. Determining which combination of these 
lifestyle factors is most strongly associated with inflammation could aid health care 
providers and researchers in developing lifestyle intervention and treatment programs that 
would be most effective in reducing systemic inflammation levels. This is especially true 
among PLWH who suffer from numerous sleep complaints [34-36] and increased 
inflammation, even when effectively undergoing ART treatment [42]. Therefore, future 
treatment or intervention studies among PLWH should incorporate components for sleep 
improvement and participation in physical activity to investigate avenues to reduce 
inflammation or disease progression (e.g., viral load).
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Table 1
Selected Baseline Population Characteristics, Psychosocial Measures, Inflammatory Markers, and Sleep 
Metrics
Categorical Characteristic n (%)
Gender
Male vs. Female 26 (58%)
Education
< High school 5 (11%)
High school or GED 10 (22%)
























Out of work 9 (21%)
Non-worker 14 (33%)
HIV/AIDS Status
HIV+ Asymptomatic 20 (44%)
HIV+ Symptomatic 20 (44%)
AIDS 5 (11%)
Continuous Characteristics Mean ± STD
Age (years) 47.1 ± 9.4
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Categorical Characteristic n (%)
Body Mass Index (kg/m2) 29.9 ± 6.7
Waist-to-Hip Ratio 0.92 ± 0.10
MVPA Minutes 121 ± 133
Perceived Stress Scale
a 16.6 ± 7.3
C-Reactive Protein (mg/L) 5.5 ± 6.1
Interluekin-6 (pg/mL) 3.6 ± 1.8
Column totals not equaling total sample size (n=45) are due to missing data. Column percentages not equaling 100% are due to rounding.
Abbreviations: MVPA=moderate-vigorous physical activity; STD=standard deviation.
a
Range of possible scores is 0-40 with higher scores being suggestive of chronic stress.
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Table 2
Baseline mean C-Reactive Protein and Interleukin-6 by Sleep Metric Levels and MVPA Minutes
Sleep Metric
C-Reactive Protein (n=45) Interleukin-6 (n=42)
Mean (95%CI) p-value Mean (95%CI) p-value
Sleep Onset
<11:46PM 1.4 (0.5-4.2) 3.7 (2.7-4.6)
>11:46PM 3.9 (1.2-12.2) 0.12 4.8 (3.9-5.7) 0.01
Wake Time
<7:22AM 2.5 (1.0-6.3) 3.5 (2.7-4.3)
>7:22AM 3.2 (1.4-7.2) 0.65 3.2 (2.4-3.9) 0.51
Total Sleep Time
<339 Minutes 6.9 (2.2-21.3) 4.9 (4.3-5.6)
>339 Minutes 2.0 (0.9-4.6) 0.05 3.6 (2.9-4.2) <0.01
Sleep Latency
<13 Minutes 2.1 (0.7-6.5) 3.8 (3.0-4.6)
>13 Minutes 1.8 (0.7-4.6) 0.80 4.6 (3.9-5.3) 0.08
Sleep Efficiency
<73% 6.4 (1.9-21.1) 4.2 (3.4-5.0)
>73% 2.0 (0.8-5.4) 0.09 3.6 (2.7-4.5) 0.19
Wake After Sleep Onset
<85 Minutes 1.7 (0.7-4.1) 4.6 (3.7-5.4)
>85 Minutes 3.8 (1.6-8.9) 0.13 4.2 (3.5-4.9) 0.43
MVPA Minutes
<70 Minutes 4.6 (1.9-11.0) 4.0 (3.3-4.7)
>70 Minutes 1.6 (0.6-3.7) 0.04 4.3 (3.5-5.1) 0.52
Values for c-reactive protein were logged transformed and back transformed for presentation. aBeta coefficients and standard errors based on 
logged-transformed c-reactive protein values. C-reactive protein adjustments: Sleep Onset = race, education, sexual orientation, and PSS; Wake 
Time = education, sexual orientation, PSS, and POC self-reevaluation subscale; Total Sleep Time = race, education, and Social Support for PA 
family subscale; Sleep Latency = race, sexual orientation, Social Support for PA family subscale, and POC self-liberation subscale; Sleep 
Efficiency = marital status, religion, race, education, Social Support for PA family subscale, POC self-reevaluation subscale, and SF-36 emotional 
wellbeing, pain, and social functioning subscales; Wake After Sleep Onset = religion, race, education, and POC self-reevaluation and 
counterconditioning subscales; MVPA Minutes = income, religion, race, education, POC self-evaluation subscale, and SF-36 emotional well-
being and mental health subscales. Interleukin-6 adjustments: Sleep Onset = employment, HIV/AIDS stage, route of infection, PSS, and SF-36 
physical functioning subscale; Wake Time = employment, PSS, POC social liberation subscale, and SF-36 physical functioning subscale; Total 
Sleep Time = route of infection, PSS, WHR, and POC social liberation subscale; Sleep Latency = route of infection, PSS, POC self-reevaluation 
and reinforcement management subscales, and SF-36 physical functioning subscale; Sleep Efficiency = employment, route of infection, and POC 
social liberation, helping relationships, and reinforcement management subscales; Wake After Sleep Onset = route of infection, PSS, WHR, POC 
self-reevaluation and counterconditioning subscales, and SF-36 limitations due to physical health subscale; MVPA Minutes = route of infection, 
and POC environmental reevaluation, self-reevaluation, social liberation, helping relationships, and reinforcement management subscales. 
Abbreviations: SE = standard error; MVPA = moderate-vigorous physical activity; 95%CI = 95% confidence interval; PSS = Perceived Stress 
Scale; POC = Process of Change; WHR = waist-to-hip ratio.
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Table 3
Baseline mean C-Reactive Protein and Interleukin-6 by Combined Sleep Metric Levels MVPA Minutes 
among Categories of Interest
Sleep Metric MVPA Level
C-Reactive Protein (n=45) Interleukin-6 (n=42)
Mean (95%CI) p-value Mean (95%CI) p-value
Sleep Onset and MVPA
<11:46PM >70 Minutes 1.1 (0.4-3.7) Referent 3.4 (2.3-4.6) Referent
>11:46PM <70 Minutes 6.5 (1.7-25.1) 0.03 5.0 (4.0-6.0) 0.02
Wake Time and MVPA
<7:22AM <70 Minutes 4.4 (1.2-16.2) 0.53 4.0 (3.0-5.1) 0.12
>7:22AM >70 Minutes 2.7 (0.9-8.2) Referent 2.9 (1.7-4.0) Referent
Total Sleep Time and MVPA
<339 Minutes <70 Minutes 6.7 (1.9-23.9) 0.01 5.3 (4.5-6.1) 0.02
>339 Minutes >70 Minutes 1.0 (0.3-3.1) Referent 4.0 (3.0-4.9) Referent
Sleep Latency and MVPA
<13 Minutes >70 Minutes 1.5 (0.4-5.1) Referent 3.7 (2.8-4.6) Referent
>13 Minutes <70 Minutes 2.4 (0.8-6.8) 0.49 4.5 (3.7-5.2) 0.14
Sleep Efficiency and MVPA
<73% <70 Minutes 7.8 (2.3-27.2) 0.02 4.3 (3.3-5.2) 0.30
>73% >70 Minutes 1.3 (0.4-4.4) Referent 3.7 (2.6-4.7) Referent
WASO and MVPA Minutes
<85 Minutes >70 Minutes 1.0 (0.4-3.0) Referent 4.6 (3.5-5.8) Referent
>85 Minutes <70 Minutes 3.9 (1.4-11.0) 0.04 4.1 (3.2-5.0) 0.46
Only comparisons between ‘most unhealthy’ and ‘healthiest’ categories are presented (see Supplemental Table A for full table). Values for c-
reactive protein were logged transformed and back transformed for presentation. C-reactive protein adjustments: Sleep Onset = race, education, 
sexual orientation, and PSS; Wake Time = education, sexual orientation, PSS, and POC self-reevaluation subscale; Total Sleep Time = race, 
education, and Social Support for PA family subscale; Sleep Latency = race, sexual orientation, Social Support for PA family subscale, and POC 
self-liberation subscale; Sleep Efficiency = marital status, religion, race, education, Social Support for PA family subscale, POC self-reevaluation 
subscale, and SF-36 emotional wellbeing, pain, and social functioning subscales; Wake After Sleep Onset = religion, race, education, and POC 
self-reevaluation and counterconditioning subscales. Interleukin-6 adjustments: Sleep Onset = employment, HIV/AIDS stage, route of infection, 
PSS, and SF-36 physical functioning subscale; Wake Time = employment, PSS, POC social liberation subscale, and SF-36 physical functioning 
subscale; Total Sleep Time = route of infection, PSS, WHR, and POC social liberation subscale; Sleep Latency = route of infection, PSS, POC 
self-reevaluation and reinforcement management subscales, and SF-36 physical functioning subscale; Sleep Efficiency = employment, route of 
infection, and POC social liberation, helping relationships, and reinforcement management subscales; Wake After Sleep Onset = route of 
infection, PSS, WHR, POC self-reevaluation and counterconditioning subscales, and SF-36 limitations due to physical health subscale; 
Abbreviations: MVPA = moderate-vigorous physical activity; 95%CI = 95% confidence interval; PSS = Perceived Stress Scale; POC = Process of 
Change; WHR = waist-to-hip ratio.
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